Prot #209639: A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion with rHuPH20, in Combination with CAB LA to Standard of

Project: Research project

Project Details

StatusActive
Effective start/end date12/12/23 → 12/12/26

Funding

  • PPD Investigator Services, LLC (Prot # 209639 AMD 2 // Prot # 209639 AMD 2)
  • GlaxoSmithKline LLC (Prot # 209639 AMD 2 // Prot # 209639 AMD 2)